Trial Profile
Non-interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Thailand)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary)
- Indications Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke
- Focus Adverse reactions
- Acronyms ETNA-AF-Thailand
- Sponsors Daiichi Sankyo Company
- 05 May 2022 Status changed from active, no longer recruiting to completed.
- 12 Oct 2021 Planned End Date changed from 1 Sep 2021 to 1 Apr 2022.
- 12 Oct 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Apr 2022.